1557. Population Pharmacokinetics of Suvratoxumab (MEDI4893), an Extended Half-life Staphylococcus aureus Alpha Toxin-Neutralizing Human Monoclonal Antibody, in Healthy Adults and Patients on Mechanical Ventilation in Intensive Care Units

BACKGROUND: Suvratoxumab (suvra), an extended half-life (~80 days), Staphylococcus aureus (SA) alpha toxin-neutralizing IgG monoclonal antibody, is under investigation for prevention of SA pneumonia in patients on mechanical ventilation (MV). We characterized the serum PK of suvra using population p...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Open Forum Infect Dis
Päätekijät: Pierre, Vadryn, Francois, Bruno, Hernandez-Illas, Martha, Sánchez Garcia, Miguel, Wu, Yuling, Eggimann, Philippe, Laterre, Pierre-Francois, Huberlant, Vincent, Viña, Lucia, Boulain, Thierry, Ruzin, Alexey, Bretonnière, Cédric, Pugin, Jerome, Trenado Álvarez, José, Bellamy, Terramika, Shoemaker, Kathryn, Ali, Omar, Lee, Nancy, Dequin, Pierre-Francois, Jafri, Hasan S, Roskos, Lorin, Colbert, Susan, Khan, Anis
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2019
Aiheet:
Abstracts
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6809240/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.1421
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia